Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - A report of the Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT) study

Yasuhiko Iino, Matsuhiko Hayashi, Tetsuya Kawamura, Tatsuo Shiigai, Yasuhiko Tomino, Kenichi Yamada, Takeyuki Kitajima, Terukuni Ideura, Akio Koyama, Tetsuzo Sugisaki, Hiromichi Suzuki, Satoshi Umemura, Yoshindo Kawaguchi, Shunya Uchida, Michio Kuwahara, Tsutomu Yamazaki, T. Konta, S. Takasaki, T. Matsunaga, T. IshimitsuH. Matsuda, S. Komatsumoto, T. Utsugi, S. Tomono, S. Nagase, K. Yamagata, K. Hirayama, K. Mase, K. Aoyagi, M. Kobayashi, H. Nakamura, H. Kikuchi, Y. Maeda, T. Okado, H. Nakamoto, S. Sugawara, Y. Handa, C. Iwahashi, T. Kashiwagi, S. Matsunobu, T. Hosoya, G. Tokudome, Y. Utsunomiya, H. Yamamoto, H. Okonogi, T. Shigematsu, Y. Miyazaki, K. Funabiki, S. Horikoshi, M. Fukui, H. Ohmuro, K. Tashiro, T. Saruta, K. Hayashi, T. Nakao, T. Okada, H. Ohi, T. Fujita, K. Nakabayashi, S. Ishizuka, A. Hasegawa, S. Mizuiri, K. Sakai, T. Suzuki, C. Ibuki, H. Yamanaka, T. Tadera, K. Nagasawa, A. Yoshimura, E. Kinugasa, H. Morita, S. Uda, S. Hara, Y. Ubara, H. Katori, F. Takemoto, T. Tagami, M. Yokota, A. Yamada, Y. Matsushita, T. Sugimoto, H. Tagawa, Y. Komatsu, T. Ohiwa, M. Futatsuyama, K. Kitazawa, T. Shibata, K. Honda, M. Endo, A. Ando, K. Ikeda, M. Yasuda, T. Ito, T. Takahashi, Y. Hori, M. Fukagawa, T. Oose, T. Shinoda, H. Yoshimoto

研究成果: Article

67 引用 (Scopus)

抄録

A 12-month, multicenter (57 clinical institutions), randomized, open-labeled trial was undertaken to compare the efficacy of the angiotensin II receptor antagonist losartan and the calcium channel blocker amlodipine in patients with proteinuric chronic kidney disease (CKD) and hypertension. A total of 117 patients (79, chronic glomerulonephritis; 14, diabetic nephropathy; 24, other CKD) were randomly allocated into two treatment groups. Losartan and amlodipine exerted the same efficacy for blood pressure (BP) control; however, losartan significantly reduced the 24-h urinary protein excretion at months 3, 6, and 12, with the reduction of 20.7%, 35.2%, 35.8%, whereas amlodipine did not change the amount of proteinuria over the 12-month study period. When patients were stratified into groups according to the level of BP control at 3 months, the reduction in urinary protein excretion by losartan was evident in the group for which a BP of <140/90 mmHg was achieved, as well as in the group for which the goal BP (<130/85 mmHg) for treatment of CKD was not achieved. When patients were stratified according to baseline urinary protein excretion, those with ≥2g/day showed a reduction in proteinuria by losartan of 23.3%, 39.4%, and 47.9% at months 3, 6, and 12, and those with <2g/day showed a reduction of 18.5% and 31.2% at months 3 and 6, respectively. No fatal adverse events were experienced in either drug group. We conclude that losartan reduced proteinuria in patients with CKD and hypertension. This positive effect may contribute to the renal protective benefit of losartan, and is beyond the magnitude of BP control.

元の言語English
ページ(範囲)21-30
ページ数10
ジャーナルHypertension Research
27
発行部数1
DOI
出版物ステータスPublished - 2004 1

Fingerprint

Amlodipine
Losartan
Chronic Renal Insufficiency
Hypertension
Kidney
Blood Pressure
Proteinuria
Therapeutics
Proteins
Angiotensin Receptor Antagonists
Calcium Channel Blockers
Diabetic Nephropathies
Glomerulonephritis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine

これを引用

Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - A report of the Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT) study. / Iino, Yasuhiko; Hayashi, Matsuhiko; Kawamura, Tetsuya; Shiigai, Tatsuo; Tomino, Yasuhiko; Yamada, Kenichi; Kitajima, Takeyuki; Ideura, Terukuni; Koyama, Akio; Sugisaki, Tetsuzo; Suzuki, Hiromichi; Umemura, Satoshi; Kawaguchi, Yoshindo; Uchida, Shunya; Kuwahara, Michio; Yamazaki, Tsutomu; Konta, T.; Takasaki, S.; Matsunaga, T.; Ishimitsu, T.; Matsuda, H.; Komatsumoto, S.; Utsugi, T.; Tomono, S.; Nagase, S.; Yamagata, K.; Hirayama, K.; Mase, K.; Aoyagi, K.; Kobayashi, M.; Nakamura, H.; Kikuchi, H.; Maeda, Y.; Okado, T.; Nakamoto, H.; Sugawara, S.; Handa, Y.; Iwahashi, C.; Kashiwagi, T.; Matsunobu, S.; Hosoya, T.; Tokudome, G.; Utsunomiya, Y.; Yamamoto, H.; Okonogi, H.; Shigematsu, T.; Miyazaki, Y.; Funabiki, K.; Horikoshi, S.; Fukui, M.; Ohmuro, H.; Tashiro, K.; Saruta, T.; Hayashi, K.; Nakao, T.; Okada, T.; Ohi, H.; Fujita, T.; Nakabayashi, K.; Ishizuka, S.; Hasegawa, A.; Mizuiri, S.; Sakai, K.; Suzuki, T.; Ibuki, C.; Yamanaka, H.; Tadera, T.; Nagasawa, K.; Yoshimura, A.; Kinugasa, E.; Morita, H.; Uda, S.; Hara, S.; Ubara, Y.; Katori, H.; Takemoto, F.; Tagami, T.; Yokota, M.; Yamada, A.; Matsushita, Y.; Sugimoto, T.; Tagawa, H.; Komatsu, Y.; Ohiwa, T.; Futatsuyama, M.; Kitazawa, K.; Shibata, T.; Honda, K.; Endo, M.; Ando, A.; Ikeda, K.; Yasuda, M.; Ito, T.; Takahashi, T.; Hori, Y.; Fukagawa, M.; Oose, T.; Shinoda, T.; Yoshimoto, H.

:: Hypertension Research, 巻 27, 番号 1, 01.2004, p. 21-30.

研究成果: Article

Iino, Y, Hayashi, M, Kawamura, T, Shiigai, T, Tomino, Y, Yamada, K, Kitajima, T, Ideura, T, Koyama, A, Sugisaki, T, Suzuki, H, Umemura, S, Kawaguchi, Y, Uchida, S, Kuwahara, M, Yamazaki, T, Konta, T, Takasaki, S, Matsunaga, T, Ishimitsu, T, Matsuda, H, Komatsumoto, S, Utsugi, T, Tomono, S, Nagase, S, Yamagata, K, Hirayama, K, Mase, K, Aoyagi, K, Kobayashi, M, Nakamura, H, Kikuchi, H, Maeda, Y, Okado, T, Nakamoto, H, Sugawara, S, Handa, Y, Iwahashi, C, Kashiwagi, T, Matsunobu, S, Hosoya, T, Tokudome, G, Utsunomiya, Y, Yamamoto, H, Okonogi, H, Shigematsu, T, Miyazaki, Y, Funabiki, K, Horikoshi, S, Fukui, M, Ohmuro, H, Tashiro, K, Saruta, T, Hayashi, K, Nakao, T, Okada, T, Ohi, H, Fujita, T, Nakabayashi, K, Ishizuka, S, Hasegawa, A, Mizuiri, S, Sakai, K, Suzuki, T, Ibuki, C, Yamanaka, H, Tadera, T, Nagasawa, K, Yoshimura, A, Kinugasa, E, Morita, H, Uda, S, Hara, S, Ubara, Y, Katori, H, Takemoto, F, Tagami, T, Yokota, M, Yamada, A, Matsushita, Y, Sugimoto, T, Tagawa, H, Komatsu, Y, Ohiwa, T, Futatsuyama, M, Kitazawa, K, Shibata, T, Honda, K, Endo, M, Ando, A, Ikeda, K, Yasuda, M, Ito, T, Takahashi, T, Hori, Y, Fukagawa, M, Oose, T, Shinoda, T & Yoshimoto, H 2004, 'Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - A report of the Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT) study', Hypertension Research, 巻. 27, 番号 1, pp. 21-30. https://doi.org/10.1291/hypres.27.21
Iino, Yasuhiko ; Hayashi, Matsuhiko ; Kawamura, Tetsuya ; Shiigai, Tatsuo ; Tomino, Yasuhiko ; Yamada, Kenichi ; Kitajima, Takeyuki ; Ideura, Terukuni ; Koyama, Akio ; Sugisaki, Tetsuzo ; Suzuki, Hiromichi ; Umemura, Satoshi ; Kawaguchi, Yoshindo ; Uchida, Shunya ; Kuwahara, Michio ; Yamazaki, Tsutomu ; Konta, T. ; Takasaki, S. ; Matsunaga, T. ; Ishimitsu, T. ; Matsuda, H. ; Komatsumoto, S. ; Utsugi, T. ; Tomono, S. ; Nagase, S. ; Yamagata, K. ; Hirayama, K. ; Mase, K. ; Aoyagi, K. ; Kobayashi, M. ; Nakamura, H. ; Kikuchi, H. ; Maeda, Y. ; Okado, T. ; Nakamoto, H. ; Sugawara, S. ; Handa, Y. ; Iwahashi, C. ; Kashiwagi, T. ; Matsunobu, S. ; Hosoya, T. ; Tokudome, G. ; Utsunomiya, Y. ; Yamamoto, H. ; Okonogi, H. ; Shigematsu, T. ; Miyazaki, Y. ; Funabiki, K. ; Horikoshi, S. ; Fukui, M. ; Ohmuro, H. ; Tashiro, K. ; Saruta, T. ; Hayashi, K. ; Nakao, T. ; Okada, T. ; Ohi, H. ; Fujita, T. ; Nakabayashi, K. ; Ishizuka, S. ; Hasegawa, A. ; Mizuiri, S. ; Sakai, K. ; Suzuki, T. ; Ibuki, C. ; Yamanaka, H. ; Tadera, T. ; Nagasawa, K. ; Yoshimura, A. ; Kinugasa, E. ; Morita, H. ; Uda, S. ; Hara, S. ; Ubara, Y. ; Katori, H. ; Takemoto, F. ; Tagami, T. ; Yokota, M. ; Yamada, A. ; Matsushita, Y. ; Sugimoto, T. ; Tagawa, H. ; Komatsu, Y. ; Ohiwa, T. ; Futatsuyama, M. ; Kitazawa, K. ; Shibata, T. ; Honda, K. ; Endo, M. ; Ando, A. ; Ikeda, K. ; Yasuda, M. ; Ito, T. ; Takahashi, T. ; Hori, Y. ; Fukagawa, M. ; Oose, T. ; Shinoda, T. ; Yoshimoto, H. / Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - A report of the Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT) study. :: Hypertension Research. 2004 ; 巻 27, 番号 1. pp. 21-30.
@article{433cb268768f4804af3e18757983af5b,
title = "Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - A report of the Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT) study",
abstract = "A 12-month, multicenter (57 clinical institutions), randomized, open-labeled trial was undertaken to compare the efficacy of the angiotensin II receptor antagonist losartan and the calcium channel blocker amlodipine in patients with proteinuric chronic kidney disease (CKD) and hypertension. A total of 117 patients (79, chronic glomerulonephritis; 14, diabetic nephropathy; 24, other CKD) were randomly allocated into two treatment groups. Losartan and amlodipine exerted the same efficacy for blood pressure (BP) control; however, losartan significantly reduced the 24-h urinary protein excretion at months 3, 6, and 12, with the reduction of 20.7{\%}, 35.2{\%}, 35.8{\%}, whereas amlodipine did not change the amount of proteinuria over the 12-month study period. When patients were stratified into groups according to the level of BP control at 3 months, the reduction in urinary protein excretion by losartan was evident in the group for which a BP of <140/90 mmHg was achieved, as well as in the group for which the goal BP (<130/85 mmHg) for treatment of CKD was not achieved. When patients were stratified according to baseline urinary protein excretion, those with ≥2g/day showed a reduction in proteinuria by losartan of 23.3{\%}, 39.4{\%}, and 47.9{\%} at months 3, 6, and 12, and those with <2g/day showed a reduction of 18.5{\%} and 31.2{\%} at months 3 and 6, respectively. No fatal adverse events were experienced in either drug group. We conclude that losartan reduced proteinuria in patients with CKD and hypertension. This positive effect may contribute to the renal protective benefit of losartan, and is beyond the magnitude of BP control.",
keywords = "Angiotensin, Hypertension, Losartan, Proteinuria, Renoprotection",
author = "Yasuhiko Iino and Matsuhiko Hayashi and Tetsuya Kawamura and Tatsuo Shiigai and Yasuhiko Tomino and Kenichi Yamada and Takeyuki Kitajima and Terukuni Ideura and Akio Koyama and Tetsuzo Sugisaki and Hiromichi Suzuki and Satoshi Umemura and Yoshindo Kawaguchi and Shunya Uchida and Michio Kuwahara and Tsutomu Yamazaki and T. Konta and S. Takasaki and T. Matsunaga and T. Ishimitsu and H. Matsuda and S. Komatsumoto and T. Utsugi and S. Tomono and S. Nagase and K. Yamagata and K. Hirayama and K. Mase and K. Aoyagi and M. Kobayashi and H. Nakamura and H. Kikuchi and Y. Maeda and T. Okado and H. Nakamoto and S. Sugawara and Y. Handa and C. Iwahashi and T. Kashiwagi and S. Matsunobu and T. Hosoya and G. Tokudome and Y. Utsunomiya and H. Yamamoto and H. Okonogi and T. Shigematsu and Y. Miyazaki and K. Funabiki and S. Horikoshi and M. Fukui and H. Ohmuro and K. Tashiro and T. Saruta and K. Hayashi and T. Nakao and T. Okada and H. Ohi and T. Fujita and K. Nakabayashi and S. Ishizuka and A. Hasegawa and S. Mizuiri and K. Sakai and T. Suzuki and C. Ibuki and H. Yamanaka and T. Tadera and K. Nagasawa and A. Yoshimura and E. Kinugasa and H. Morita and S. Uda and S. Hara and Y. Ubara and H. Katori and F. Takemoto and T. Tagami and M. Yokota and A. Yamada and Y. Matsushita and T. Sugimoto and H. Tagawa and Y. Komatsu and T. Ohiwa and M. Futatsuyama and K. Kitazawa and T. Shibata and K. Honda and M. Endo and A. Ando and K. Ikeda and M. Yasuda and T. Ito and T. Takahashi and Y. Hori and M. Fukagawa and T. Oose and T. Shinoda and H. Yoshimoto",
year = "2004",
month = "1",
doi = "10.1291/hypres.27.21",
language = "English",
volume = "27",
pages = "21--30",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - A report of the Japanese losartan therapy intended for the global renal protection in hypertensive patients (JLIGHT) study

AU - Iino, Yasuhiko

AU - Hayashi, Matsuhiko

AU - Kawamura, Tetsuya

AU - Shiigai, Tatsuo

AU - Tomino, Yasuhiko

AU - Yamada, Kenichi

AU - Kitajima, Takeyuki

AU - Ideura, Terukuni

AU - Koyama, Akio

AU - Sugisaki, Tetsuzo

AU - Suzuki, Hiromichi

AU - Umemura, Satoshi

AU - Kawaguchi, Yoshindo

AU - Uchida, Shunya

AU - Kuwahara, Michio

AU - Yamazaki, Tsutomu

AU - Konta, T.

AU - Takasaki, S.

AU - Matsunaga, T.

AU - Ishimitsu, T.

AU - Matsuda, H.

AU - Komatsumoto, S.

AU - Utsugi, T.

AU - Tomono, S.

AU - Nagase, S.

AU - Yamagata, K.

AU - Hirayama, K.

AU - Mase, K.

AU - Aoyagi, K.

AU - Kobayashi, M.

AU - Nakamura, H.

AU - Kikuchi, H.

AU - Maeda, Y.

AU - Okado, T.

AU - Nakamoto, H.

AU - Sugawara, S.

AU - Handa, Y.

AU - Iwahashi, C.

AU - Kashiwagi, T.

AU - Matsunobu, S.

AU - Hosoya, T.

AU - Tokudome, G.

AU - Utsunomiya, Y.

AU - Yamamoto, H.

AU - Okonogi, H.

AU - Shigematsu, T.

AU - Miyazaki, Y.

AU - Funabiki, K.

AU - Horikoshi, S.

AU - Fukui, M.

AU - Ohmuro, H.

AU - Tashiro, K.

AU - Saruta, T.

AU - Hayashi, K.

AU - Nakao, T.

AU - Okada, T.

AU - Ohi, H.

AU - Fujita, T.

AU - Nakabayashi, K.

AU - Ishizuka, S.

AU - Hasegawa, A.

AU - Mizuiri, S.

AU - Sakai, K.

AU - Suzuki, T.

AU - Ibuki, C.

AU - Yamanaka, H.

AU - Tadera, T.

AU - Nagasawa, K.

AU - Yoshimura, A.

AU - Kinugasa, E.

AU - Morita, H.

AU - Uda, S.

AU - Hara, S.

AU - Ubara, Y.

AU - Katori, H.

AU - Takemoto, F.

AU - Tagami, T.

AU - Yokota, M.

AU - Yamada, A.

AU - Matsushita, Y.

AU - Sugimoto, T.

AU - Tagawa, H.

AU - Komatsu, Y.

AU - Ohiwa, T.

AU - Futatsuyama, M.

AU - Kitazawa, K.

AU - Shibata, T.

AU - Honda, K.

AU - Endo, M.

AU - Ando, A.

AU - Ikeda, K.

AU - Yasuda, M.

AU - Ito, T.

AU - Takahashi, T.

AU - Hori, Y.

AU - Fukagawa, M.

AU - Oose, T.

AU - Shinoda, T.

AU - Yoshimoto, H.

PY - 2004/1

Y1 - 2004/1

N2 - A 12-month, multicenter (57 clinical institutions), randomized, open-labeled trial was undertaken to compare the efficacy of the angiotensin II receptor antagonist losartan and the calcium channel blocker amlodipine in patients with proteinuric chronic kidney disease (CKD) and hypertension. A total of 117 patients (79, chronic glomerulonephritis; 14, diabetic nephropathy; 24, other CKD) were randomly allocated into two treatment groups. Losartan and amlodipine exerted the same efficacy for blood pressure (BP) control; however, losartan significantly reduced the 24-h urinary protein excretion at months 3, 6, and 12, with the reduction of 20.7%, 35.2%, 35.8%, whereas amlodipine did not change the amount of proteinuria over the 12-month study period. When patients were stratified into groups according to the level of BP control at 3 months, the reduction in urinary protein excretion by losartan was evident in the group for which a BP of <140/90 mmHg was achieved, as well as in the group for which the goal BP (<130/85 mmHg) for treatment of CKD was not achieved. When patients were stratified according to baseline urinary protein excretion, those with ≥2g/day showed a reduction in proteinuria by losartan of 23.3%, 39.4%, and 47.9% at months 3, 6, and 12, and those with <2g/day showed a reduction of 18.5% and 31.2% at months 3 and 6, respectively. No fatal adverse events were experienced in either drug group. We conclude that losartan reduced proteinuria in patients with CKD and hypertension. This positive effect may contribute to the renal protective benefit of losartan, and is beyond the magnitude of BP control.

AB - A 12-month, multicenter (57 clinical institutions), randomized, open-labeled trial was undertaken to compare the efficacy of the angiotensin II receptor antagonist losartan and the calcium channel blocker amlodipine in patients with proteinuric chronic kidney disease (CKD) and hypertension. A total of 117 patients (79, chronic glomerulonephritis; 14, diabetic nephropathy; 24, other CKD) were randomly allocated into two treatment groups. Losartan and amlodipine exerted the same efficacy for blood pressure (BP) control; however, losartan significantly reduced the 24-h urinary protein excretion at months 3, 6, and 12, with the reduction of 20.7%, 35.2%, 35.8%, whereas amlodipine did not change the amount of proteinuria over the 12-month study period. When patients were stratified into groups according to the level of BP control at 3 months, the reduction in urinary protein excretion by losartan was evident in the group for which a BP of <140/90 mmHg was achieved, as well as in the group for which the goal BP (<130/85 mmHg) for treatment of CKD was not achieved. When patients were stratified according to baseline urinary protein excretion, those with ≥2g/day showed a reduction in proteinuria by losartan of 23.3%, 39.4%, and 47.9% at months 3, 6, and 12, and those with <2g/day showed a reduction of 18.5% and 31.2% at months 3 and 6, respectively. No fatal adverse events were experienced in either drug group. We conclude that losartan reduced proteinuria in patients with CKD and hypertension. This positive effect may contribute to the renal protective benefit of losartan, and is beyond the magnitude of BP control.

KW - Angiotensin

KW - Hypertension

KW - Losartan

KW - Proteinuria

KW - Renoprotection

UR - http://www.scopus.com/inward/record.url?scp=10744221480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744221480&partnerID=8YFLogxK

U2 - 10.1291/hypres.27.21

DO - 10.1291/hypres.27.21

M3 - Article

C2 - 15055252

AN - SCOPUS:10744221480

VL - 27

SP - 21

EP - 30

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 1

ER -